Last update Sept. 9, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
O-[(1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetyl]glycolic acid is Acemetacin in Chemical name.
Is written in other languages:O-[(1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetyl]glycolic acid belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 66 | % |
Molecular weight | 416 | daltons |
Protein Binding | > 90 | % |
VD | 0.5 - 0.7 | l/Kg |
pKa | 3.26 | - |
Tmax | 2.5 | hours |
T½ | 4.5 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Acemetacin, a compound of indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID). Its pharmacological activity is due to acemetacin and its main metabolite, indomethacin. It is used in rheumatoid arthritis, osteoarthritis, and low back pain, and for postoperative pain and inflammation. Oral administration in several doses per day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
The literature on this drug is very scarce.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.